MOLOGEN AG
MOLOGEN AG to present poster at ASCO Annual Meeting
DGAP-News: MOLOGEN AG / Key word(s): Conference 2015-05-27 / 09:57 --------------------------------------------------------------------- PRESS RELEASE N° 08 / 2015 of 05/27/2015 MOLOGEN AG to present poster at ASCO Annual Meeting Berlin, May 27, 2015 - The biotechnology company MOLOGEN AG will present a poster on the phase II clinical trial "IMPACT" with the cancer immunotherapy MGN1703 at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago (May 29-June 2, 2015). The poster will mainly outline updated data on a subgroup of patients with long-term progression-free survival (PFS) from the IMPACT trial in colorectal cancer. The evaluation performed in April 2015 reported a PFS ranging from 44 to 51 months for these patients. In the IMPACT study patients with prior response to induction therapy appeared to benefit most from the treatment with MGN1703. The study design of the currently ongoing pivotal trial IMPALA is based on the findings from the IMPACT trial. The poster will be featured on May 30, from 08.00 am to 11.30 am at the general poster session "Developmental Therapeutics-Immunotherapy". Abstract details: Abstract Number: 3049 Title: "A subgroup with improved overall survival from the phase II IMPACT study: Maintenance therapy of metastatic colorectal cancer patients with the TLR-9 agonist MGN1703" Abstract Session: May 30, 2015 from 8.00 am - 11.30 am. For more information please visit ASCO's website: http://am.asco.org/ For more information on the IMPACT and IMPALA trials please visit www.clinicaltrials.gov. About IMPACT IMPACT (Immunomodulatory MGN1703 in Patients with Advanced Colorectal Carcinoma with Disease Control after Initial First-line Therapy) was a phase II, randomized, placebo-controlled, double-blind, multicenter clinical study aiming to determine the efficacy of MGN1703 as switch maintenance therapy following first-line chemotherapy with or without bevacizumab in patients with metastatic colorectal cancer. Patients included in the IMPACT study had stabilization, or partial or complete remission of their disease after receiving first-line therapy for 4.5 to 6 months. The patients were randomized to receive either MGN1703 or placebo twice per week. The treatment was continued until tumor progression was observed. The primary endpoint of the study was to determine progression-free survival of the patients. Secondary study endpoints included overall survival, progression-free survival from start of induction therapy, response rates and safety, as well as collection of immunological and pharmacodynamic data. About MGN1703 MGN1703 is an innovative DNA-based TLR9 agonist developed by MOLOGEN. It broadly activates the immune system. This activation can be utilized to enable the immune system to better recognize and combat cancer cells. Due to this mechanism of action, MGN1703 can be applied to different indications of cancer. MOLOGEN AG MOLOGEN AG is a biotechnology company specialized in the research and clinical development of cancer immunotherapies and DNA vaccines against infectious diseases. The cancer immunotherapy MGN1703 is the company's lead product and best-in-class TLR9 agonist. It is currently developed for first-line maintenance treatment of colorectal cancer (pivotal randomized trial) and small cell lung cancer (randomized controlled trial). A second clinical-stage product is MGN1601, a therapeutic vaccination for the treatment of renal cancer. A phase I/II clinical study has already been completed successfully. With unique, patented technologies and innovative products, MOLOGEN is pioneering immunotherapies. MOLOGEN AG is a publicly listed company, headquartered in Berlin. The shares (ISIN DE0006637200) are listed in the Prime Standard of the German Stock Exchange. www.mologen.com Memberships in associations: Biotechnologieverbund Berlin-Brandenburg (bbb) e.V. | BIO Deutschland e.V. | DECHEMA - Society for chemical technology and biotechnology e.V. | German industrial association of biotechnology (DIB) | Association for the Promotion of Science and Humanities in Germany | Association of German biotechnology companies (VBU) | Association of researching manufacturers of pharmaceuticals e.V. (VFA) | Association of the chemical industry e.V. (VCI) MIDGE(R), dSLIM(R), EnanDIM(R) and MOLOGEN(R) are registered trademarks of MOLOGEN AG. Contact Claudia Nickolaus Head of Investor Relations & Corporate Communications Tel: +49 - 30 - 84 17 88 - 38 Fax: +49 - 30 - 84 17 88 - 50 investor@mologen.com Note about risk for future predictions Certain information in this report contains forward-looking statements or the corresponding statements with negation or versions deviating from this or comparable terminology. These are described as forward-looking statements. In addition, all of the information given here that refers to planned or future results of business areas, key financial figures, developments of the financial situation or other financial figures or statistical data, is to be understood as such forward-looking statements. The company points out to investors that they should not rely on these forward-looking statements as predictions about actual future events. The company is not obligated and refuses to accept any liability for the forward-looking statements and has no obligation to update such statements in order to accurately reflect the current situation. --------------------------------------------------------------------- 2015-05-27 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: MOLOGEN AG Fabeckstraße 30 14195 Berlin Germany Phone: 030 / 841788-0 Fax: 030 / 841788-50 E-mail: presse@mologen.com Internet: www.mologen.com ISIN: DE0006637200 WKN: 663720 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart End of News DGAP News-Service --------------------------------------------------------------------- 361959 2015-05-27
Latest News
Latest Reports
Upcoming Events
No Events found
Webcasts
No Webcasts found